IBA Announces Expansion of Collaboration with MorphoSys's AbD Serotec
Advertisement
IBA GmbH announced the signing of a second license agreement with MorphoSys AG regarding recombinant antibody purification using IBA's proprietary Strep-tag® technology. The original research license agreement dating back to the year 2000 has now been complemented with a second license agreement rendering the commercial use of IBA's Strep-tag patent rights for custom service purification of antibodies by AbD Serotec - a business unit of MorphoSys AG.
The license granted by IBA is worldwide and non-exclusive. According to the company, recent IBA developments in the Strep-tag field had proven to be advantageous compared to other tag-systems for automated batch purification of recombinant antibodies. Financial details of the license agreement were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous